Abstract |
The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/ metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.
|
Authors | Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balazs Halmos |
Journal | Oncotarget
(Oncotarget)
Vol. 5
Issue 20
Pg. 9546-63
(Oct 30 2014)
ISSN: 1949-2553 [Electronic] United States |
PMID | 25337673
(Publication Type: Journal Article, Review)
|
Chemical References |
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases
- Axl Receptor Tyrosine Kinase
- AXL protein, human
|
Topics |
- Animals
- Humans
- Molecular Targeted Therapy
- Neoplasms
(drug therapy, enzymology)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Proto-Oncogene Proteins
(antagonists & inhibitors, metabolism)
- Receptor Protein-Tyrosine Kinases
(antagonists & inhibitors, metabolism)
- Axl Receptor Tyrosine Kinase
|